Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global analysis of cancer cell responses to USP9X inhibition

ABSTRACT: K-GG ubiquitin profiling of UO-31 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). Sample IDs:#1-5 Control 30 min UO-31#6-10 WEHI-092 30 min UO-31#11-15 Control 360 min UO-31#16-20 WEHI-092 360 min UO-31#21-25 Control 24 h UO-31#26-30 WEHI-092 24 h UO-31

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Kidney Epithelial Cell, Cell Culture

SUBMITTER: Philipp Schenk

LAB HEAD: David Komander

PROVIDER: PXD073754 | Pride | 2026-04-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	checksum.txt	Txt
	kGG_1.raw	Raw
	kGG_10.raw	Raw
	kGG_11.raw	Raw
	kGG_12.raw	Raw

Items per page:

1 - 5 of 32

Publications

Global analysis of cancer cell responses to USP9X inhibition.

Schenk Philipp P Devine Shane M SM Cobbold Simon A SA Geoghegan Niall D ND Kyran Elizabeth L EL Ang Ching-Seng CS Alexandrovics Jack A JA Calleja Dale J DJ Multari Dylan H DH Vaibhav Vineet V Lu Bernadine G C BGC Klemm Theresa A TA Dagley Laura F LF Lowes Kym N KN Williamson Nicholas A NA Eichhorn Pieter J A PJA Ng Ashley P AP Feltham Rebecca R Komander David D

The EMBO journal 20260407 9

The ubiquitin-specific protease (USP) USP9X is a human deubiquitinase (DUB) with a large number of described targets and cellular roles. In cancer, USP9X is found as an oncogene or as a tumour suppressor depending on context, and its utility as a target for cancer therapy remains unclear. We here describe WEHI-092, a piperazine-based USP9X-specific small-molecule inhibitor, which binds to a unique region in the USP9X Fingers-subdomain, distinct from known DUB-inhibitor binding sites. Using prote ...[more]

PMID: 41946992

Similar Datasets

Global analysis of cancer cell responses to USP9X inhibition

Project description:K-GG ubiquitin profiling of SK-MEL-2 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). Sample IDs:#31-35 Control 30 min SK-MEL-2#36-40 WEHI-092 30 min SK-MEL-2#41-45 Control 360 min SK-MEL-2#46-50 WEHI-092 360 min SK-MEL-2#51-55 Control 24 h SK-MEL-2#56-60 WEHI-092 24 h SK-MEL-2

2026-04-09 | PXD073775 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h.Sample IDs:#1-5 Control 30 min DLD-1#6-10 FT671 30 min DLD-1#11-15 WEHI-092 30 min DLD-1#16-20 Control 360 min DLD-1#21-25 FT671 360 min DLD-1#26-30 WEHI-092 360min DLD-1#31-35 Control 30 min MDA-MB-231#36-40 WEHI-092 30 min MDA-MB-231#41-45 Control 360 min MDA-MB-231#46-50 WEHI-092 360 min MDA-MB-231#51-55 Control 24 h MDA-MB-231#56-60 WEHI-092 24 h MDA-MB-231

2026-04-09 | PXD073869 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231

2026-04-09 | PXD075275 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:K-GG ubiquitin profiling of SK-MEL-2 and UO-31 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset is the matched global quantitative proteomics data.Sample IDs:#1-5 Control 30 min UO-31#6-10 WEHI-092 30 min UO-31#11-15 Control 360 min UO-31#16-20 WEHI-092 360 min UO-31#21-25 Control 24 h UO-31#26-30 WEHI-092 24 h UO-31#31-35 Control 30 min SK-MEL-2#36-40 WEHI-092 30 min SK-MEL-2#41-45 Control 360 min SK-MEL-2#46-50 WEHI-092 360 min SK-MEL-2#51-55 Control 24 h SK-MEL-2#56-60 WEHI-092 24 h SK-MEL-2

2026-04-09 | PXD073798 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:Global proteomics dataset for K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231

2026-04-09 | PXD074673 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:Treatment of cancer cells MDA-MB-231 and MiaPaca2 with WEHI-092 (10 uM, 24 h) or FT709 (10 uM, 24 h). Sample key of raw file in ZIP folder: #1-6 MDA-MB-231 DMSO (untreated); #13-18 MDA-MB-231 FT709; #19-24 MDA-MB-231 WEHI-092; #25-30 MiaPaca2 DMSO (untreated); #37-42 MiaPaca2 FT709; #43-48 MiaPaca2 WEHI-092.

2026-04-09 | PXD074729 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:Global proteomics experiment using USP9X siRNA (and control) MDA-MB-231 cells with (10 µM, 24 h) and without USP9X inhibitor treatment using WEHI-092 and untreated (DMSO) control (P5448, see sample key). Global proteomics experiment profiling cancer cell lines treated with USP9X inhibitor WEHI-092 (10 µM, 24 h) and untreated (DMSO) control.P4971 1-5 UO-31 cells, untreatedP4971 6-10 UO-31 cells, WEHI-092P4971 11-15 A549 cells, untreatedP4971 16-20 A549 cells, WEHI-092P4971 21-25 DLD-1 cells, untreatedP4971 26-30 DLD-1 cells, WEHI-092P4971 41-45 OVCAR8 cells, untreatedP4971 46-50 OVCAR8 cells, WEHI-092P4971 51-55 SK-MEL-2 cells, untreatedP4971 56-60 SK-MEL-2 cells, WEHI-092P5080 11-15 HMEC-1 cells, untreatedP5080 16-20 HMEC-1 cells, WEHI-092

2026-04-09 | PXD062674 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:Mass spectrometry-based 3X-FLAG-Ub-VS deubiquitinase (DUB) competition assay with cell extracts (DUB IP-MS) profiling MCF-7 cells with regard to specificity of WEHI-092, a selective inhibitor for USP9X. Sample key: #1-5 Untreated; #6-10 Ub-VS pre-treatment; #11-15 WEHI-092 treated (50 µM, 60 min).

2026-04-09 | PXD074545 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:HDX-MS experiment using selective USP9X inhibitors WEHI-092, FT709 with recombinant catalytic domain USP9X.

2026-04-09 | PXD062754 | Pride

Expression data from transformed WT and HGPS cell lines, including HGPS cells after knock-down of BRD4

Project description:Primary skin fibroblasts from a HGPS patient and an age-matched control wild-type individual were challenged in a standard transformation assay by retroviral introduction of TERT (T), V12-HRAS (R) and SV40 large and small T antigens (S). Knock-down of BRD4 in this TRS-HGPS cell line (TRS-HGPS-shBRD4) was achieved by retroviral introduction of independent shRNAs (shBRD4-1 to -3) Abstract: Advanced age and DNA damage accumulation are strong risk factors for cancer. The premature-aging disorder Hutchinson Gilford Progeria Syndrome (HGPS) provides a unique opportunity to study the interplay between DNA damage and aging-associated tumor mechanisms, since HGPS patients do not develop tumors despite elevated levels of DNA damage. Here, we have used HGPS patient cells to identify a protective mechanism to oncogenesis. We find that HGPS cells are resistant to neo-plastic transformation. This resistance is mediated by the bromodomain protein BRD4, which exhibits altered genome-wide binding patterns in transformation-resistant cells leading to inhibition of oncogenic de-differentiation. BRD4 also in-hibits, albeit to a lower extent, the tumorigenic potential of transformed cells from healthy individuals and BRD4-mediated tumor protection is clinically relevant, since a BRD4 gene signature predicts positive clinical outcome in breast and lung cancer. Our results demonstrate a protective function for BRD4 and suggest tissue-specific functions for BRD4 in tumorigenesis. 2 biological replicates are included for TRS-WT and TRS-HGPS cell lines. 3 biological replicates are included for TRS-HGPS-shBRD4 (derived from 3 independent shRNAs against BRD4)

2014-10-02 | E-GEOD-60519 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data